Showing results 71 - 80 of 311
We highlight some of the key features of the current UK regime for plant variety protection, and underscore strategic considerations for managing PBRs as part of an international IP portfolio....
Antibody-drug conjugates (ADCs) are a biotherapeutic modality typically used for the treatment of cancer....
GJE is pleased to announce that the firm has formed an alliance with the German patent and trade mark firm Wächtershäuser & Hartz (W&H)...
GJE is delighted that we have been recommended as a leading firm of patent attorneys in the IP Stars 2025 rankings. Published by Managing IP, the annual IP Stars survey recommends the world’s leadin...
GJE has been eagerly awaiting the decision in G 1/24 from the European Patent Office’s Enlarged Board of Appeal, which was announced yesterday. The referral relates to fundamental principles for cla...
We summarise the developing approach of the UK and European patent offices in assessing the patentability of AI and LLMs in the world of Health Tech...
Read our June 2025 patent law update, including updates from the UK, the European Patent Office (EPO) and the WIPO/PCT...
GJE is proud to learn that Peter Arrowsmith, Arnie Clarke and Lucy Samuels have been named as Patent Stars in the IP Stars 2025 rankings....
Read our May 2025 patent law update, including updates from the UK, the European Patent Office (EPO) and the WIPO/PCT...
In Generics, Teva & Glenmark v AstraZeneca, the High Court restated how inventive step and sufficiency are assessed in the UK considering “plausibility”...